When is Elective Pelvic Lymph Node Irradiation Indicated in Definitive Radiotherapy for Localized Prostate Cancer?

被引：3
作者：
Mendenhall, William M. [1 ,2 ]
Hoppe, Bradford S. [2 ]
Nichols, R. Charles [2 ]
Henderson, Randal H. [2 ]
Mendenhall, Nancy P. [2 ]
机构：
[1] Univ Florida, Dept Radiat Oncol, Coll Med, Gainesville, FL USA
[2] Univ Florida, Proton Therapy Inst, Jacksonville, FL USA
来源：
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS | 2013年 / 36卷 / 06期
关键词：
prostate cancer; radiotherapy; pelvic lymph nodes; HIGH-RISK; RADICAL PROSTATECTOMY; ANDROGEN SUPPRESSION; WHOLE-PELVIS; RADIATION; NEOADJUVANT; METASTASES; TRIAL; ADENOCARCINOMA; SURVIVAL;
D O I：
10.1097/COC.0b013e31823a53fa
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The objective is to define the role of elective pelvic node irradiation (EPNI) in patients treated with definitive radiotherapy for clinically localized prostate cancer. Review of the pertinent literature revealed few prospective randomized trials that evaluated the efficacy of EPNI. Although EPNI may reduce the risk of regional recurrence, its impact on biochemical progression-free survival and overall survival is unclear. Depending on the extent of the radiotherapy fields, EPNI may result in a modest increase in acute toxicity and an even smaller increase in late toxicity. EPNI may reduce the risk of regional failure in patients with high-risk prostate cancer with a likelihood of lymph node positivity of 15%. Although it may result in improved biochemical progression-free survival, its impact is likely modest, at best. However, EPNI should be considered for patients with a high risk of regional disease.
引用
收藏
页码：644 / 647
页数：4
相关论文
共 25 条
  • [1] WHOLE PELVIC RADIOTHERAPY VERSUS PROSTATE ONLY RADIOTHERAPY IN THE MANAGEMENT OF LOCALLY ADVANCED OR AGGRESSIVE PROSTATE ADENOCARCINOMA
    Aizer, Ayal A.
    Yu, James B.
    McKeon, Anne M.
    Decker, Roy H.
    Colberg, John W.
    Peschel, Richard E.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2009, 75 (05): : 1344 - 1349
  • [2] WHOLE-PELVIS RADIOTHERAPY IN COMBINATION WITH INTERSTITIAL BRACHYTHERAPY: DOES COVERAGE OF THE PELVIC LYMPH NODES IMPROVE TREATMENT OUTCOME IN HIGH-RISK PROSTATE CANCER?
    Bittner, Nathan
    Merrick, Gregory S.
    Wallner, Kent E.
    Butler, Wayne M.
    Galbreath, Robert
    Adamovich, Edward
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2010, 76 (04): : 1078 - 1084
  • [3] DOSIMETRIC STUDY OF PELVIC PROTON RADIOTHERAPY FOR HIGH-RISK PROSTATE CANCER
    Chera, Bhishamjit S.
    Vargas, Carlos
    Morris, Christopher G.
    Louis, Debbie
    Flampouri, Stella
    Yeung, Daniel
    Duvvuri, Srividya
    Li, Zuofeng
    Mendenhall, Nancy Price
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2009, 75 (04): : 994 - 1002
  • [4] Long-Term Follow-up of Patients with Prostate Cancer and Nodal Metastases Treated by Pelvic Lymphadenectomy and Radical Prostatectomy: The Positive Impact of Adjuvant Radiotherapy
    Da Pozzo, Luigi F.
    Cozzarini, Cesare
    Briganti, Alberto
    Suardi, Nazareno
    Salonia, Andrea
    Bertini, Roberto
    Gallina, Andrea
    Bianchi, Marco
    Fantini, Gemma V.
    Bolognesi, Angelo
    Fazio, Ferruccio
    Montorsi, Francesco
    Rigatti, Patrizio
    [J]. EUROPEAN UROLOGY, 2009, 55 (05) : 1003 - 1011
  • [5] Survival Benefit of Radical Prostatectomy in Lymph Node-Positive Patients with Prostate Cancer
    Engel, Jutta
    Bastian, Patrick J.
    Baur, Helmut
    Beer, Volker
    Chaussy, Christian
    Gschwend, Juergen E.
    Oberneder, Ralph
    Rothenberger, Karl H.
    Stief, Christian G.
    Hoelzel, Dieter
    [J]. EUROPEAN UROLOGY, 2010, 57 (05) : 754 - 761
  • [6] Prognostic factors in lymph node metastases of prostatic cancer patients: the size of the metastases but not extranodal extension independently predicts survival
    Fleischmann, A.
    Schobinger, S.
    Markwalder, R.
    Schumacher, M.
    Burkhard, F.
    Thalmann, G. N.
    Studer, U. E.
    [J]. HISTOPATHOLOGY, 2008, 53 (04) : 468 - 475
  • [7] Androgen suppression plus radiation versus radiation alone for patients with D1 (pN+) adenocarcinoma of the prostate (results based on a national prospective randomized trial, RTOG 85-31)
    Lawton, CA
    Winter, K
    Byhardt, R
    Sause, WT
    Hanks, GE
    Russell, AH
    Rotman, M
    Porter, A
    McGowan, DG
    DelRowe, JD
    Pilepich, MV
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1997, 38 (05): : 931 - 939
  • [8] An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: Updated analysis of RTOG 94-13, with emphasis on unexpected hormone/radiation interactions
    Lawton, Colleen A.
    DeSilvio, Michelle
    Roach, Mack, III
    Uhl, Valery
    Kirsch, Robert
    Seider, Michael
    Rotman, Marvin
    Jones, Christopher
    Asbell, Sucha
    Valicenti, Richard
    Hahn, Stephen
    Thomas, Charles R., Jr.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2007, 69 (03): : 646 - 655
  • [9] RTOG GU RADIATION ONCOLOGY SPECIALISTS REACH CONSENSUS ON PELVIC LYMPH NODE VOLUMES FOR HIGH-RISK PROSTATE CANCER
    Lawton, Colleen A. F.
    Michalski, Jeff
    El-Naqa, Issam
    Buyyounouski, Mark K.
    Lee, W. Robert
    Menard, Cynthia
    O'Meara, Elizabeth
    Rosenthal, Seth A.
    Ritter, Mark
    Seider, Michael
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2009, 74 (02): : 383 - 387
  • [10] Pathological findings and oncological control afforded by radical prostatectomy in men with high-risk prostate cancer: a single-centre study
    Masson-Lecomte, Alexandra
    Hupertan, Vincent
    Comperat, Eva
    Vaessen, Christophe
    Chartier-Kastler, Emmanuel
    Cussenot, Olivier
    Bitker, Marc-Olivier
    Roupret, Morgan
    [J]. WORLD JOURNAL OF UROLOGY, 2011, 29 (05) : 665 - 670
123